Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Bright Minds Biosciences Inc (DRUG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/24/2025: DRUG (3-star) is a STRONG-BUY. BUY since 64 days. Simulated Profits (80.69%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $91.93
1 Year Target Price $91.93
| 4 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 3253.08% | Avg. Invested days 49 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 438.04M USD | Price to earnings Ratio - | 1Y Target Price 91.93 |
Price to earnings Ratio - | 1Y Target Price 91.93 | ||
Volume (30-day avg) 6 | Beta -0.35 | 52 Weeks Range 23.18 - 70.23 | Updated Date 10/26/2025 |
52 Weeks Range 23.18 - 70.23 | Updated Date 10/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.98 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -18.31% | Return on Equity (TTM) -30.79% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 375284777 | Price to Sales(TTM) - |
Enterprise Value 375284777 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.07 | Shares Outstanding 7088639 | Shares Floating 3006225 |
Shares Outstanding 7088639 | Shares Floating 3006225 | ||
Percent Insiders 20.4 | Percent Institutions 67.33 |
Upturn AI SWOT
Bright Minds Biosciences Inc
Company Overview
History and Background
Bright Minds Biosciences Inc. was founded to develop novel therapeutics for neuropsychiatric disorders, pain, and epilepsy. They focus on developing serotonin 5-HT2C receptor agonists.
Core Business Areas
- Drug Discovery and Development: Bright Minds Biosciences focuses on discovering and developing novel small molecule therapeutics. They primarily target serotonin receptors for treating neuropsychiatric disorders, epilepsy, and pain.
Leadership and Structure
The leadership team consists of experienced individuals in drug development and neuroscience. The organizational structure is typical of a biotech company, with research and development, clinical operations, and administrative functions.
Top Products and Market Share
Key Offerings
- BMB-101: BMB-101 is Bright Minds' lead compound, a selective 5-HT2C receptor agonist being developed for Dravet Syndrome. There is no market share as this product is not yet on the market. Competitors developing similar products for Dravet Syndrome include Zogenix (acquired by UCB), and GW Pharmaceuticals (acquired by Jazz Pharmaceuticals).
- BMB-202: BMB-202 is an investigational therapy being developed for treatment resistant depression (TRD). The product is in preclinical stage. Competitors developing similar products for TRD include Axsome Therapeutics and COMPASS Pathways.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. There is growing research and development in the neuropsychiatric disorders, pain, and epilepsy spaces.
Positioning
Bright Minds Biosciences is a clinical-stage biotechnology company with a focus on developing novel therapies. Their competitive advantage lies in the selectivity and potential efficacy of their 5-HT2C receptor agonists.
Total Addressable Market (TAM)
The global market for epilepsy therapeutics is estimated to be over $10 billion. The TRD market is also significant. Bright Minds is positioned to capture a share of these markets if their drug candidates are approved.
Upturn SWOT Analysis
Strengths
- Novel drug candidates targeting 5-HT2C receptor
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Early-stage clinical development
- Limited financial resources
- High risk of clinical trial failure
Opportunities
- Potential to address unmet medical needs in neuropsychiatric disorders, pain, and epilepsy
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
Threats
- Competition from other pharmaceutical companies
- Regulatory hurdles
- Unsuccessful clinical trials
- Economic downturn affecting R&D funding
Competitors and Market Share
Key Competitors
- UCB (UCBJF)
- Jazz Pharmaceuticals (JAZZ)
- Axsome Therapeutics (AXSM)
- COMPASS Pathways (CMPS)
Competitive Landscape
Bright Minds faces competition from established pharmaceutical companies. Their success hinges on demonstrating superior efficacy and safety of their drug candidates.
Growth Trajectory and Initiatives
Historical Growth: The company's growth is primarily driven by advancements in its clinical programs.
Future Projections: Future growth depends on positive clinical trial outcomes and potential partnerships.
Recent Initiatives: Focus on advancing BMB-101 through clinical trials and developing additional drug candidates.
Summary
Bright Minds Biosciences is a development-stage biotech company focused on novel neuropsychiatric drugs. Its strength is its innovative approach targeting serotonin receptors, but it faces challenges in funding and clinical trial success. Positive clinical trial results could significantly improve the company's prospects. Key risks involve regulatory hurdles and competition from larger pharmaceutical companies. The company's progress will depend on successful execution of clinical trials and strategic partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bright Minds Biosciences Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2021-03-22 | Co-Founder, CEO, President & Director Mr. Ian McDonald | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://brightmindsbio.com |
Full time employees - | Website https://brightmindsbio.com | ||
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatry and neurology indications. Bright Minds Biosciences Inc. has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was founded in 2017 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.